In this issue of MCT, three articles from the NCI's Preclinical Chemoradiotherapy Testing Consortium (PCRTC) are presented that each demonstrates a story of success. Each cooperative agreement team's results are briefly summarized, and both the importance and the limitations of these studies are discussed. These preclinical studies used agents from the Cancer Therapy Evaluation Program portfolio to develop the foundation for translation into clinical trials. The structure of these studies was based on the prior work of the PCRTC that laid out the methodology for optimizing potential translation. Rigor and reproducibility have been a continuing focus of the PCRTC, with a key feature being the requirement for dose measurement and calibration to be traceable to national standards. Through the application of the consortium's prior work establishing the standards for translation, each group generated promising data with high translational potential. See related article by Valvo et al., p. 843 See related article by Dragojevic et al., p. 859 See related article by Lu et al., p. 920.

©2025 American Association for Cancer Research.

在本期的MCT中，介绍了NCI的临床前化学放射治疗测试联盟（PCRTC）的三篇文章，每一篇文章都展示了成功的案例。简要总结了每个合作协议团队的结果，并讨论了这些研究的重要性和局限性。这些临床前研究使用了癌症治疗评估计划组合中的代理来开发转化为临床试验的基础。这些研究的结构基于PCRTC之前的工作，该工作制定了优化潜在转化的方法论。严谨性和可重复性一直是PCRTC持续关注的重点，其中一个重要特征是要求剂量测量和校准可以追溯到国家标准。通过应用联盟先前建立的转换标准，每个小组都生成了具有高转化潜力的有希望的数据。

参见Valvo等人的相关文章，第843页

参见Dragojevic等人的相关文章，第859页

参见Lu等人的相关文章，第920页